Compatibility of next-generation first-line antiretrovirals... : Current Opinion in HIV and AIDS
Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis …

Background Higher doses of rifampicin may improve treatment outcomes and reduce the
duration of tuberculosis (TB) therapy. However, drug–drug interactions with antiretroviral …

The World Health Organization guidelines recommend that individuals living with HIV
receive≥ 6 months of isoniazid preventive therapy, including pregnant women. Yet, plasma …

Obesity is a global epidemic and people living with HIV (PLWH) are showing similar obesity
trends to those in the general population. Obesity is manifested by several physiological …

Background: Tenofovir-diphosphate (TFV-DP) in dried blood spots (DBS) is an objective
long-term adherence measure, but data are limited on its ability to predict virologic …

Background: HIV is produced in lymphoid tissues (LT) and stored on the follicular dendritic
cell network in LT. When antiretroviral therapy is started, plasma viremia decays in 2 phases; …

Background Obesity is increasingly prevalent among people with HIV (PWH) and can
possibly result in suboptimal antiretroviral drug (ARV) exposure and response. However …

Pre-exposure prophylaxis (PrEP) is considered one of the five “pillars” by UNAIDS to reduce
HIV transmission. Moreover, it is a tool for female self-protection against HIV, making it …

Background High-dose rifampicin is considered to shorten anti-TB treatment duration but its
effect on antiretroviral metabolism is unknown. Objectives To assess the effect of doubling …

Clinical data on the relationships of cytochrome P450 (CYP2) B6 516G> T polymorphisms
with efavirenz-induced central nervous system (CNS) side effects and virological response …